首页> 美国卫生研究院文献>International Journal of Environmental Research and Public Health >How Do Pharmaceutical Companies Overcome a Corporate Productivity Crisis? Business Diversification into Medical Devices for Growth Potential
【2h】

How Do Pharmaceutical Companies Overcome a Corporate Productivity Crisis? Business Diversification into Medical Devices for Growth Potential

机译:制药公司如何克服公司生产力危机?商业多样化进入生长潜力的医疗设备

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The purpose of this study was to analyze the performance of pharmaceutical companies’ business diversification into medical devices in terms of their technical efficiency (TE) as compared to that of traditional pharmaceutical companies. For a total of 174 externally audited pharmaceutical companies engaged in the drug product business between 2008 and 2019, pharmaceutical companies were classified into two groups according to medical device business diversification. The TE of pharmaceutical companies that diversify the medical device business was lower than that of traditional pharmaceutical companies. However, in terms of the meta-technology ratio (MTR) calculated using meta-frontier analysis, pharmaceutical companies diversified into medical devices showed higher MTR than the traditional pharmaceutical company group. The results imply that the corporate performance growth potential of traditional pharmaceutical companies is lower than that of pharmaceutical companies that have diversified into the medical device business.
机译:本研究的目的是将制药公司商业多样化的表现分析到与传统制药公司相比其技术效率(TE)的医疗器械的表现。总共有174家外部审计的制药公司从事2008年至2019年期间的药品业务,根据医疗器械商业多样化,制药公司分为两组。多元化医疗器械业务的制药公司TE低于传统制药公司的制药公司。然而,就使用元前沿分析计算的元技术比率(MTR)而言,在医疗器械中多样化的制药公司比传统的制药公司集团的MTR显示出更高的MTR。结果意味着传统制药公司的企业绩效增长潜力低于经医疗器械业务多元化的制药公司。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号